Netivudine
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 584840

CAS#: 84558-93-0

Description: Netivudine is an inhibitor of varicella zoster virus.


Chemical Structure

img
Netivudine
CAS# 84558-93-0

Theoretical Analysis

MedKoo Cat#: 584840
Name: Netivudine
CAS#: 84558-93-0
Chemical Formula: C12H14N2O6
Exact Mass: 282.09
Molecular Weight: 282.252
Elemental Analysis: C, 51.07; H, 5.00; N, 9.93; O, 34.01

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Netivudine; 882C87; BW882C87; BW-882C87; BW 882C87; DRG 0179; DRG-0179; DRG0179;

IUPAC/Chemical Name: 2,4(1H,3H)-Pyrimidinedione, 1-beta-D-arabinofuranosyl-5-(1-propynyl)-

InChi Key: QLOCVMVCRJOTTM-SDNRWEOFSA-N

InChi Code: InChI=1S/C12H14N2O6/c1-2-3-6-4-14(12(19)13-10(6)18)11-9(17)8(16)7(5-15)20-11/h4,7-9,11,15-17H,5H2,1H3,(H,13,18,19)/t7-,8-,9+,11-/m1/s1

SMILES Code: O=C1NC(C(C#CC)=CN1[C@H]2[C@H]([C@@H]([C@@H](CO)O2)O)O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:
Biological target: Netivudine is a nucleoside analogue with potent anti-varicella zoster virus activity.
In vitro activity: TBD
In vivo activity: TBD

Preparing Stock Solutions

The following data is based on the product molecular weight 282.25 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: TBD
In vitro protocol: TBD
In vivo protocol: TBD

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Söltz-Szöts J, Tyring S, Andersen PL, Lucht RF, McKendrick MW, Diaz Perez JL, Shukla S, Fiddian AP. A randomized controlled trial of acyclovir versus netivudine for treatment of herpes zoster. International Zoster Study Group. J Antimicrob Chemother. 1998 May;41(5):549-56. PubMed PMID: 9630408.

2: Peck R, Wiggs R, Callaghan J, Wootton R, Crome P, Fraser I, Frick L, Posner J. Inhibition of dihydropyrimidine dehydrogenase by 5-propynyluracil, a metabolite of the anti-varicella zoster virus agent netivudine. Clin Pharmacol Ther. 1996 Jan;59(1):22-31. PubMed PMID: 8549030.

3: McGuigan C, Perry A, Yarnold CJ, Sutton PW, Lowe D, Miller W, Rahim SG, Slater MJ. Synthesis and evaluation of some masked phosphate esters of the anti-herpesvirus drug 882C (netivudine) as potential antiviral agents. Antivir Chem Chemother. 1998 May;9(3):233-43. PubMed PMID: 9875402.

4: Fillastre JP, Godin M, Legallicier B, Chretien P, Bidault R, Gillotin C, Wooton R, Posner J, Peck RW. Pharmacokinetics of netivudine, a potent anti-varicella zoster virus drug, in patients with renal impairment. J Antimicrob Chemother. 1996 May;37(5):965-74. PubMed PMID: 8737146.

5: Le Roy F, Godin M, Legallicler B, Fillastre JP, Bidault R, Posner J, Peck RW. Pharmacokinetics of netivudine in haemodialysis patients. J Antimicrob Chemother. 1996 Nov;38(5):913-5. PubMed PMID: 8961067.

6: Peck RW, Crome P, Wood MJ, McKendrick MW, Bannister B, Mandal BK, Crooks RJ. Multiple dose netivudine, a potent anti-varicella zoster virus agent, in healthy elderly volunteers and patients with shingles. J Antimicrob Chemother. 1996 Mar;37(3):583-97. PubMed PMID: 9182115.

7: Snoeck R, Andrei G, De Clercq E. Current pharmacological approaches to the therapy of varicella zoster virus infections: a guide to treatment. Drugs. 1999 Feb;57(2):187-206. Review. PubMed PMID: 10188760.

8: Purifoy DJ, Beauchamp LM, de Miranda P, Ertl P, Lacey S, Roberts G, Rahim SG, Darby G, Krenitsky TA, Powell KL. Review of research leading to new anti-herpesvirus agents in clinical development: valaciclovir hydrochloride (256U, the L-valyl ester of acyclovir) and 882C, a specific agent for varicella zoster virus. J Med Virol. 1993;Suppl 1:139-45. Review. PubMed PMID: 8245881.

9: Wood MJ, McKendrick MW, Bannister B, Mandal BK, Peck RW, Crooks RJ. Preliminary pharmacokinetics and safety of 882C87 in patients with herpes zoster. J Med Virol. 1993;Suppl 1:154-7. PubMed PMID: 8245884.

10: Buick AR, Sheung CT. Determination of 1-(beta-D-arabinofuranosyl)-5-(1-propynyl)-uracil and a metabolite, 5-propynyluracil, in plasma using ASTED (automated sequential trace enrichment of dialysates) combined, on-line, with high-performance liquid chromatography. J Chromatogr. 1993 Jul 23;617(1):65-70. PubMed PMID: 8376539.

11: Darby G. Acyclovir--and beyond. J Int Med Res. 1994;22 Suppl 1:33A-42A. Review. PubMed PMID: 8063023.

12: Fiddian AP. Antiviral drugs in development for herpes zoster. Scand J Infect Dis Suppl. 1996;100:51-4. Review. PubMed PMID: 9163026.

13: Nikkels AF, Piérard GE. Recognition and treatment of shingles. Drugs. 1994 Oct;48(4):528-48. Review. PubMed PMID: 7528128.

14: Wareham D. Postherpetic neuralgia. Clin Evid. 2005 Dec;(14):1017-25. Review. PubMed PMID: 16620445.

15: Wareham D. Postherpetic neuralgia. Clin Evid. 2004 Dec;(12):1182-93. Review. Update in: Clin Evid. 2005 Dec;(14):1017-25. PubMed PMID: 15865712.

16: Easterbrook P, Wood MJ. Successors to acyclovir. J Antimicrob Chemother. 1994 Sep;34(3):307-11. Review. PubMed PMID: 7829405.

17: Cooper JD, Sheung CT, Buick AR. Automated sequential trace enrichment of dialysates combined with high-performance liquid chromatography and automated heart-cutting for the determination of the nucleoside 1-(beta-D-arabinofuranosyl)-5-(1-propynyl)uracil and its metabolite 5-propynyluracil in urine. J Chromatogr. 1994 Jan 14;652(1):15-21. PubMed PMID: 8014223.

18: Peck RW, Wootton R, Lee DR, Jackson SH, Posner J. The bioavailability and disposition of 1-(beta-D-arabinofuranosyl)-5-(1-propynyl)uracil (882C87), a potent, new anti-varicella zoster virus agent. Br J Clin Pharmacol. 1995 Feb;39(2):143-9. PubMed PMID: 7742152; PubMed Central PMCID: PMC1364951.

19: Peck RW, Weatherley BC, Wootton R, Crome P, Holdich TA, Posner J. Pharmacokinetics and tolerability of single oral doses of 882C87, a potent, new anti-varicella-zoster virus agent, in healthy volunteers. Antimicrob Agents Chemother. 1995 Jan;39(1):20-7. PubMed PMID: 7695306; PubMed Central PMCID: PMC162478.

20: Lacey SF, Suzutani T, Powell KL, Purifoy DJ, Honess RW. Analysis of mutations in the thymidine kinase genes of drug-resistant varicella-zoster virus populations using the polymerase chain reaction. J Gen Virol. 1991 Mar;72 ( Pt 3):623-30. PubMed PMID: 1848597.